Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren’s disease, a scoping review

Current evidence supports a pragmatic, individualized approach. Rituximab remains the foundation of SjD-associated lymphoma therapy, typically combined with chemotherapy. However, current evidence is limited by small, heterogeneous cohorts, with pooled reporting across lymphoma types/regimens and limited safety reporting. Prospective SjD-specific studies, with regimen-level reporting of efficacy and safety are needed. Uniform endpoints that capture both hematologic and autoimmune activity, and lymphoma type stratification should be applied.